Anti-biofilm plant metabolite 4-ethoxybenzoic acid for synergistic antimicrobial formulations

Overview

4-ethoxybenzoic acid (4EB) is a naturally derived metabolite, structurally related to compounds isolated from gesho, an East African traditional medicinal plant. The proposed research evaluates whether 4EB can work synergistically with quaternary ammonium compounds (quats) to create a broad-spectrum antimicrobial formulation effective against both planktonic cells and biofilms at low concentrations. This combination approach addresses a critical need for anti-pathogenic agents that prevent biofilm formation without driving resistance, while extending coverage to Gram-negative organisms that 4EB alone does not inhibit.

The value proposition centers on reducing reliance on high-concentration biocides. By using 4EB in combination with quats, formulators can potentially achieve effective microbial control at lower active-ingredient concentrations, reducing material costs and regulatory burden while limiting selective pressure for resistant strains.

Technical specifications

Key features and observed activities:

• At low concentrations (0.04 to 0.16 percent), 4EB is anti-pathogenic, preventing biofilm formation without killing cells, reducing biofilm formation by nearly 90 percent relative to untreated controls
• At higher concentrations (0.7 percent or greater), 4EB is bactericidal, achieving a 6 log reduction
• 4EB prevents biofilm formation by Gram-positive pathogens including Staphylococcus aureus and Streptococcus mutans, as well as the yeast Candida albicans
• 4EB potentiates vancomycin sensitivity in S. aureus, affects biofilm matrix production, and reduces cell membrane hydrophobicity
• A structure-activity analysis identified 4EB as the most anti-pathogenic gesho-derived compound, while related compounds such as methylgallate exhibit both bactericidal and anti-biofilm activity
• 4EB alone does not affect biofilm formation by the Gram-negative pathogen Pseudomonas aeruginosa, motivating combination with quats for broad-spectrum coverage

Proposed validation approach:

• Evaluate interactions between 4EB and selected quats using a grid design
• Conduct growth inhibition and biofilm prevention experiments for S. aureus, C. albicans, and P. aeruginosa, alone and in co-culture, in 96-well plates analyzed by plate reader and plate count
• Test the most effective 4EB-quat combinations following ASTM E2274 standard methods
• Investigate mechanism of action, including potential cellular targets and non-specific effects such as cell membrane damage, to guide development of more potent analogs

Technology readiness level

This research is at an early-to-mid stage of development. The core activity of 4EB has been characterized through in vitro biofilm prevention and bactericidal assays against multiple microbial species, and a structure-activity analysis has been completed across related compounds. The proposed work, estimated at nine months, will advance the technology by identifying synergistic 4EB-quat combinations, validating them against standardized test methods (ASTM E2274), and beginning mechanistic studies to inform next-generation analogs. Funding will support key personnel, laboratory supplies, and core facility charges. Further development, including formulation optimization, scaled-up synthesis, and regulatory evaluation, would be required prior to commercialization.